^
Association details:
Biomarker:Chr t(14;16)
Cancer:Multiple Myeloma
Drug:Ninlaro (ixazomib) (Proteasome inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Survival Benet of Ixazomib, Lenalidomide and Dexamethasone (IRD) Over Lenalidomide and Dexamethasone (Rd) in Relapsed and Refractory Multiple Myeloma Patients in Routine Clinical Practice

Published date:
08/04/2020
Excerpt:
The overall response rate (ORR) was 73.0% in the IRD cohort vs 66.2% in the RD cohort….Median OS was significantly improved in the IRD cohort (36.6 months vs 26.0 months p=0.008); in patients with 1–3 prior relapses median OS was not yet reached for the IRD cohort (NR vs 27.1 months p=0.002). A higher percentage of patients in the IRD cohort were still alive at 6 months (88.9% vs 83.4%), 12 months (76.8% vs 71.5%), and 24 months (66.4% vs 52.7%),...High-risk features as defined by the presence at least one cytogenetic abnormality including t(4;14), t(14;16), or del(17p13) were present in 11.8% (15/127) patients in the IRD cohort and 8.8% (19/217) patients in the RD cohort. Among those patients in the IRD cohort whose disease was considered high-risk, one patient reached VGPR, six reached PR, four reached MR, two had stable disease (SD) and two progressed (PD).
DOI:
10.21203/rs.3.rs-45379/v1